Autonomix Medical, Inc. Completes Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use
30 janv. 2024 09h05 HE
|
Autonomix Medical, Inc.
Autonomix now wholly owns development and commercialization rights to its technology in all indications Re-acquisition broadens Autonomix’s development and strategic opportunities THE WOODLANDS,...
QHSLab Integrates Digital Medicine Assessments into Prominent Electronic Health Record (EHR) Company
30 janv. 2024 08h30 HE
|
QHSLab, Inc.
This integration allows QHSLab access to more than 160,000 providers that are the exact match for target providers. WEST PALM BEACH, FL, Jan. 30, 2024 (GLOBE NEWSWIRE) -- QHSLab, Inc. (the...
Autonomix Medical, Inc. (NASDAQ: AMIX) Commences Trading on NASDAQ
29 janv. 2024 08h05 HE
|
Autonomix Medical, Inc.
Company developing potential breakthrough technology for the nervous system Initially targeting multi-billion-dollar pancreatic cancer market THE WOODLANDS, TX., Jan. 29, 2024 (GLOBE NEWSWIRE)...
Autonomix Medical, Inc. Announces Closing of $11.2 Million in Gross Proceeds from Initial Public Offering
26 janv. 2024 16h05 HE
|
Autonomix Medical, Inc.
Shares to begin trading on NASDAQ on January 29, 2024 under the ticker symbol “AMIX” THE WOODLANDS, TX., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the...
SeaStar Medical Appoints David A. Green as Chief Financial Officer
11 janv. 2024 16h05 HE
|
SeaStar Medical Holding Corporation
DENVER, Jan. 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation...
Autonomix Medical, Inc. to Present at the Startup Investing Webinar
11 janv. 2024 09h00 HE
|
Autonomix Medical, Inc.
Live webcast roundtable discussion featuring Autonomix, Knightscope, and Infinity Fuel on Thursday, January 11th at 2:00 PM ET THE WOODLANDS, TX, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Autonomix...
SeaStar Medical Issued U.S. Patent with Broad Claims Covering Use of the Selective Cytopheretic Device for Multiple Clinical Indications
09 janv. 2024 08h30 HE
|
SeaStar Medical Holding Corporation
DENVER, Jan. 09, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation...
Autonomix Medical, Inc. Provides Business Overview and Highlights Upcoming Milestones
04 janv. 2024 10h00 HE
|
Autonomix Medical, Inc.
Company developing potential breakthrough technology for the nervous system Patented two-fold technology that can potentially detect problematic neural signals and ablate nerves in one simple...
GLUCOTRACK ANNOUNCES EARLY ACCURACY DATA FOR ITS IMPLANTABLE CONTINUOUS GLUCOSE MONITOR
02 janv. 2024 12h33 HE
|
GlucoTrack, Inc.
Rutherford, NJ, Jan. 02, 2024 (GLOBE NEWSWIRE) -- GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a medical device company focused on the design, development, and commercialization...
GLUCOTRACK ANNOUNCES 180-DAY EXTENSION TO REGAIN COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT
30 nov. 2023 17h39 HE
|
GlucoTrack, Inc.
Rutherford, NJ, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with...